Chemistry:Tedatioxetine

From HandWiki
Revision as of 02:58, 9 March 2024 by Sherlock (talk | contribs) (url)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Tedatioxetine
Tedatioxetine.svg
Tedatioxetine ball-and-stick model.png
Clinical data
Other namesLu AA24530; Lu-AA-24530
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC18H21NS
Molar mass283.43 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Tedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]

Tedatioxetine is reported to act as a triple reuptake inhibitor (serotonin > norepinephrine > dopamine) and 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptor antagonist.[2][3][4][5]

As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[6][7]

On May 10, 2016, all work on tedatioxetine stopped.[8]

A Chinese patent shows that there has been interest in this compound outside of Lundbeck.[9]

See also

References

  1. "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs"]. First Word Pharma. 5 September 2007. http://www.firstwordpharma.com/node/88051?tsid=17#axzz3xkIEA5eH. 
  2. Stensbol TB, Miller S, "4-[2-(4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression", US patent 2010144788, published 10 June 2010, assigned to H Lundbeck AS
  3. Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. 19 May 2008. pp. 206. ISBN 978-0-521-88663-5. https://books.google.com/books?id=zqvVZOea2JAC&pg=PA206. Retrieved 22 November 2011. 
  4. Encyclopedia of Psychopharmacology. Springer. 30 August 2010. pp. 105. ISBN 978-3-540-68698-9. https://books.google.com/books?id=qoyYobgX0uwC&pg=PA105. Retrieved 22 November 2011. 
  5. 5.0 5.1 "Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009. http://www.fiercebiotech.com/press-releases/lu-aa24530-shows-positive-results-major-depressive-disorder-phase-ii-study. 
  6. "Pipeline of Lundbeck". http://investor.lundbeck.com/pipeline.cfm. 
  7. "Tedatioxetine". UK Medicines Information. http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4990. 
  8. "Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800023694. 
  9. Cao, Longji; Jianchuang Xin & Xiangping Yang, "Compound for preparing 4-(2-(4-methylphenylthio))phenylpiperidine, and preparation method and use thereof", WO patent 2015090160, published 2015-06-25

External links